HONG KONG – Samsung Bioepis Co. Ltd. has inked a deal for the mainland China market with investment firm C-Bridge Capital Partners LLC, which will generate a new company: Affamed Therapeutics. The licensing agreement covers multiple biosimilar candidates from Samsung Bioepis. This includes its third-wave biosimilars SB-11 and SB-12, which are ranibizumab and eculizumab candidates based on Genentech Inc.'s Lucentis and Alexion Pharmaceuticals Inc.'s Soliris, respectively.
HONG KONG – The Indian Ministry of Chemicals and Fertilizers has exempted foreign makers of new drugs patented under India's Patents Act 1970 (39 of 1970) from price regulation for five years.
HONG KONG – The Indian Ministry of Chemicals and Fertilizers has exempted foreign makers of new drugs patented under India's Patents Act 1970 (39 of 1970) from price regulation for five years.
HONG KONG – The late December IPO of Shanghai Junshi Biosciences Co., shortly after the company got a green light for the first made-in-China immunotherapy treatment, delivered a strong close to 2018 for the country's biotech industry. But it did little to mask the huge losses that Chinese pharma stocks suffered through the year.
HONG KONG – South Korean biotech company Samsung Bioepis Co. Ltd. has entered a licensing agreement with China's 3Sbio Inc. to expand its biosimilars business to mainland China. The agreement covers multiple biosimilar candidates from the Incheon-based Samsung Bioepis, including SB-8, a biosimilar to blockbuster anti-VEGF antibody Avastin (bevacizumab, Genentech Inc./Roche Holding AG) that is undergoing phase III trials.
